POLICY: Vesicular Monoamine Transporter Type 2 Inhibitors - Austedo Prior Authorization Policy
Defines prior authorization requirements and medical necessity criteria for Austedo (deutetrabenazine) and Austedo XR for prescription benefit coverage under Cigna-administered health benefit plans, including FDA-approved indications and exclusions.
Austedo XR was added to the policy.
Annual reviews in 2023, 2024, and 2025 noted; 2023 and 2024 recorded 'No criteria changes.'
Coverage Summary
Defines prior authorization requirements and medical necessity criteria for Austedo (deutetrabenazine) and Austedo XR for prescription benefit coverage under Cigna-administered health benefit plans, including FDA-approved indications and exclusions. Austedo and Austedo XR are indicated in adults for chorea associated with Huntington's disease and tardive dyskinesia. Coverage stance: covered_with_criteria (Prior Authorization recommended under the Vesicular Monoamine Transporter Type 2 Inhibitors - Austedo Prior Authorization Policy for Cigna-administered plans).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.